Last updated on December 2018

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension


Brief description of study

The objective of this clinical trial is to compare the efficacy and safety of an initial triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral treatment regimen (macitentan, tadalafil, placebo) in newly diagnosed, treatment-nave patients with pulmonary arterial hypertension.

Clinical Study Identifier: NCT02558231

Contact Investigators or Research Sites near you

Start Over

UCSD Health Sciences

La Jolla, CA United States
  Connect »

UCLA Medical Center

Los Angeles, CA United States
  Connect »

Cleveland Clinic Florida

Weston, FL United States
  Connect »

Tufts Medical Center

Boston, MA United States
  Connect »

The Christ Hospital

Cincinnati, OH United States
  Connect »

UPMC Presbyterian

Pittsburgh, PA United States
  Connect »

Houston Methodist Hospital

Houston, TX United States
  Connect »

H pital Erasme

Brussels, Belgium
  Connect »

Mayo Clinic Jacksonville

Jacksonville, FL United States
  Connect »

Northwestern University

Chicago, IL United States
  Connect »

University of New Mexico Hospital

New Orleans, LA United States
  Connect »

The Alfred Hospital

Melbourne, Australia
  Connect »

AKH Wien

Wien, Austria
  Connect »

CHU de Bic tre

Le Kremlin-Bicêtre, France
  Connect »

VUmc Amsterdam

Amsterdam, Netherlands
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.